{"id":"W4412370560","doi":"10.1007/s40120-025-00784-0","title":"Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis","year":2025,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"EMD Serono; Idorsia Pharmaceuticals; Schweizerische Multiple Sklerose Gesellschaft; Ministry of Health, Labour and Welfare; Fondazione Cariplo; Multiple Sclerosis Society; Shionogi; Argenx; Atara Biotherapeutics; Genentech; Amicus Therapeutics; Novartis; Celgene; Ministry of Education, Culture, Sports, Science and Technology; BioCryst; Sanofi; GW Pharmaceuticals; TG Therapeutics; Samsung; Bristol-Myers Squibb; CSL Behring; Pfizer; Biogen; F. Hoffmann-La Roche; Greenwich Biosciences; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; Sanofi Genzyme; Patient-Centered Outcomes Research Institute","keywords":"Medicine; Ofatumumab; Multiple sclerosis; Neurology; Natalizumab; Internal medicine; Dermatology; Immunology; Psychiatry; Rituximab; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004987353,0.0003361939,0.000708605,0.0007085098,0.000394479,0.0007012953,0.0003396957,0.0005056209,0.00157603],"category_scores_gemma":[0.005306635,0.0001346544,0.001633293,0.0007679818,0.0002677354,0.0007176292,0.0005825865,0.0007575225,0.0002854948],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005167267,"about_ca_system_score_gemma":0.0004862037,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001087683,"about_ca_topic_score_gemma":0.001393167,"domain_scores_codex":[0.9984151,0.0005577795,0.0002115322,0.0002546592,0.0003794816,0.0001815553],"domain_scores_gemma":[0.9939982,0.001072256,0.003479746,0.0002844789,0.0005976215,0.0005678823],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.03117856,0.0004623257,0.9312564,0.0004191471,0.0017538,0.0001421966,0.0003329485,0.0006941968,0.0006362965,0.00006179076,0.0006733066,0.03238898],"study_design_scores_gemma":[0.0006459994,0.005856215,0.9908661,0.00006824725,0.0007017847,0.0002195945,0.00008272775,0.0003180841,0.0003175086,0.0001095314,0.0007933084,0.00002098881],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960632,0.001763761,0.0001644239,0.0001229469,0.00001594104,0.00005328745,0.001080906,0.000008657705,0.0007268921],"genre_scores_gemma":[0.9979184,0.0002782849,0.0001077327,0.00004590198,0.00002683239,0.00004559627,0.001317027,0.000001883103,0.000258282],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004987353,"threshold_uncertainty_score":0.02637601,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02200023117692603,"score_gpt":0.2685536937391004,"score_spread":0.2465534625621743,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}